Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC By Ogkologos - April 18, 2025 733 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an integrated analysis of the pivotal phase II regional TRUST-I and global TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers MOST POPULAR NHS England change of chief executive – what does it mean... August 19, 2021 Cómo prepararse para su exploración por TEP-TC April 1, 2021 Got the COVID Blues? August 12, 2020 Reunión anual de la American Society of Clinical Oncology (ASCO) de... June 3, 2022 Load more HOT NEWS What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic... FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC Tailored Psychotherapy Eases Depression in People with Advanced Cancer
